[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Kragujevac\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,58,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100650313","vitamin-d-status-and-clinical-outcomes-in-locally-advanced-cervical-cancer-100650313",false,"NCT07743918","Vitamin D Status and Clinical Outcomes in Locally Advanced Cervical Cancer","Pretreatment Vitamin D Status and Clinical Outcomes in Patients With Locally Advanced Cervical Cancer Undergoing Definitive Chemoradiotherapy","CERVITAL","Inclusion Criteria:\n\n* Female patients aged 18 to 80 years.\n* Histopathologically confirmed cervical cancer.\n* Locally advanced disease, FIGO 2018 stage IIB to IVA.\n* Eastern Cooperative Oncology Group performance status 0-1.\n* Planned treatment with definitive concurrent chemoradiotherapy.\n* Signed informed consent.\n* Ability to comply with study procedures and follow-up visits.\n\nExclusion Criteria:\n\n* Age under 18 years.\n* Pregnancy or lactation.\n* Previous or synchronous diagnosis of another pelvic or abdominal malignancy.\n* Previous chemotherapy.\n* Previous radiotherapy.\n* Previous treatment with immune checkpoint inhibitors.\n* Current or recent vitamin D supplementation.\n* Interrupted oncological treatment.\n* Failure to attend scheduled follow-up visits.\n* Incomplete medical documentation.","FEMALE","18 Years","80 Years",{"count":21,"type":22},100,"ESTIMATED","7 Months","OBSERVATIONAL","Background. Definitive chemoradiotherapy represents the standard therapeutic approach for the management of locally advanced cervical cancer. Vitamin D plays an important role in the regulation of cellular growth and differentiation, immune system function, and the modulation of inflammatory processes. Hypovitaminosis D may be associated with the development of cervical cancer, whereas its impact on the effects of oncological treatment remains insufficiently elucidated. The aim of this study is to investigate the predictive significance of vitamin D in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy.\n\nMethods. This study is designed as a clinical, observational, prospective cohort study. Patients with locally advanced cervical cancer undergoing definitive chemoradiotherapy at the Clinic for Radiation Oncology, University Clinical Center Kragujevac, will be enrolled. Vitamin D concentrations will be measured before the initiation of treatment in both serum and cervical lavage samples. Baseline vitamin D levels will be analyzed in relation to treatment outcome and the occurrence of acute radiation toxicity. In addition, vitamin D concentrations will be evaluated in the context of clinical and morphological parameters, therapeutic response, and treatment-related toxicity.\n\nExpected Results. This study will enable an assessment of the actual significance of pretreatment vitamin D concentrations in serum and cervical lavage as a potential novel biomarker in relation to chemoradiosensitivity and\u002For chemoradioresistance of cervical cancer, as well as the response of organs at risk, in patients with locally advanced disease.",[27,28],"Locally Advanced Cervical Cancer","Vitamin D Concentration",[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Locally advanced cervical cancer;","vitamin D;","hypovitaminosis D;","serum vitamin D;","cervical lavage;","chemoradiotherapy;","radiotherapy;","cisplatin;","brachytherapy;","treatment response;","radiation toxicity;","RECIST 1.1;","CTCAE;","chemoradiosensitivity;","chemoradioresistency","RECRUITING","2026-07-31",{"date":48,"type":49},"2026-08-04","ACTUAL",{"date":51,"type":49},"2026-01-01",{"date":53,"type":22},"2034-09-01",{"name":55,"class":56},"University of Kragujevac","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":65,"minAge":18,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100646555","impact-of-chronic-microplastic-exposure-on-radiotherapy-of-head-and-neck-cancer-patients-clinical-and-translational-oncology-study-100646555","NCT07690631","Impact of Chronic MICROplastic Exposure on RADiotherapy of Head and Neck Cancer Patients: Clinical and Translational Oncology Study:","MICRORAD","Inclusion Criteria:\n\n* Any stage head and neck cancer patients\n* Eastern Cooperative Oncology Group performance status 0-2\n* Undergoing radiotherapy with\u002Fwithout cisplatin chemopotentiation\n* Signed informed consent\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Mental illness\n* Prior or concurrent malignancies\n* Immunotherapy or immunosuppressive therapy\n* Immune diseases","ALL",{"count":67,"type":22},500,"MICRORAD is a pioneering 48-month translational research project that investigates the potential health and environmental impacts of micro- and nanoplastics (MNPs) released from medical devices when exposed to ionizing radiation. In radiation oncology, thermoplastic masks (TPMs) are standard immobilization tools, particularly for head and neck (HN) cancer patients. Globally, approximately 2.65 million TPMs are used annually in the radiotherapy of HN cancer patients and with an additional 8 to 10 million for other tumor types. TPMs are repeatedly subjected to high-energy X-rays and frequent handling, raising concerns about polymer degradation and the release of MNPs, which may interfere with treatment efficacy or contribute to radiation toxicity.\n\nMICRORAD is the first translational study to explore this phenomenon by integrating clinical oncology, materials science, radiobiology, and data science. The project will analyze radiation-induced changes in TPMs, quantify MNP release, and assess their biological effects through in vitro, in vivo, and clinical studies.\n\nUsing advanced detection techniques, the project will characterize MNPs and trace their biodistribution, while a clinical pilot will correlate MNP exposure with treatment outcomes. Data integration, biostatistics, and AI-based modeling will support the translation of findings into clinical guidelines, policy briefs, and public communication.\n\nA multidisciplinary team will collaborate to ensure real-world impact. By bridging oncology and environmental health, MICRORAD aims to establish eco-oncology as a new field, contributing to patient safety and sustainable innovation.",[70,71],"Head and Neck Cancer","Microplastic Exposure",[73,74,75,63,76],"Head and neck cancer","Microplastics","thermoplastics mask","MNPs","NOT_YET_RECRUITING","2026-07-13",{"date":80,"type":49},"2026-07-15",{"date":82,"type":22},"2026-09",{"date":84,"type":22},"2030-10",{"name":55,"class":56},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":65,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":111,"locationsCount":4},"100636228","fertility-impact-of-microplastics---advancing-countermeasures-and-tracking-100636228","NCT07562958","Fertility Impact of Microplastics - Advancing Countermeasures and Tracking","FERTIMPACT","Inclusion Criteria:\n\n* Men: 18-55 years and women: 18-45 years (premenopausal).\n* Residence: ≥ 2 years in the participating region.\n* Ability to give informed consent and complete questionnaires (diet, lifestyle, occupational exposure).\n* Willingness to provide required samples: semen, serum, stool for men and for women serum, stool, follicular fluid and endometrial sample.\n* Availability for study visits and compliance with pre-analytical rules: Abstinence 2-7 days before semen collection and timed sampling in women (e.g., follicular phase or per protocol).\n* For patient cohort: diagnosed reproductive disorder per site SOPs (e.g., male factor infertility, endometriosis, diminished ovarian reserve).\n* For control cohort: no known infertility diagnosis; trying to conceive or healthy volunteers.\n* Necessary for all participants will be possess the ability to understand the information contained in the \"informed consent\" document.\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Acute febrile illness or active urogenital\u002Freproductive tract infection in the last 4 weeks.\n* Systemic therapies likely to confound biomarkers within prespecified windows: chemotherapy\u002Fradiotherapy (past 12 months), high-dose corticosteroids\u002Fimmunosuppressants (past 3 months), hormonal stimulation outside scheduled ART cycles per protocol.\n* Substance abuse (investigator judgment) impeding consent\u002Fcompliance.","55 Years",{"count":95,"type":22},1000,"FERTIMPACT is a prospective clinical study based on the hypothesis that exposure to micro- and nanoplastics (MNPs) is associated with impaired reproductive function. The study will quantify MNPs in human reproductive biospecimens (semen, follicular fluid, endometrial samples, stool and serum) and evaluate their association with clinically relevant fertility parameters, including semen, follicular fluid, and endometrial samples quality, and assisted reproductive technology (ART) outcomes. By integrating biomonitoring with standardized clinical assessment, the study aims to provide robust evidence on exposure-effect relationships in real-world populations undergoing infertility evaluation. This will contribute to improved understanding of environmental determinants of reproductive health and support future risk assessment strategies.",[98,99,100],"Infertility","Microplastics Exposure","Fertility",[100,102,103,104],"microplastics","IVF","micronanoplastics","2026-04-28",{"date":107,"type":49},"2026-05-01",{"date":109,"type":22},"2027-09",{"date":84,"type":22},{"name":55,"class":56},""]